Oral blood pressure augmenting agents for intravenous vasopressor weaning  

作　　者：John C Robinson Mariam ElSaban Nathan J Smischney Patrick M Wieruszewski 

机构地区：[1]Department of Pharmacy,Mayo Clinic,Phoenix,AZ 85054,United States [2]Department of Anesthesiology and Perioperative Medicine,Mayo Clinic,Rochester,MN 55905,United States [3]Department of Anesthesiology,Mayo Clinic,Rochester,MN 55905,United States [4]Department of Pharmacy,Mayo Clinic,Rochester,MN 55905,United States

出　　处：《World Journal of Clinical Cases》2024年第36期6892-6904,共13页世界临床病例杂志（英文）

摘　　要：Intravenous(IV)vasopressors are essential in the management of hypotension and shock.Initiation of oral vasoactive agents to facilitate weaning of IV vasopressors to liberate patients from the intensive care unit is common despite conflicting evidence regarding the benefits of this practice.While midodrine appears to be the most frequently studied oral vasoactive agent for this purpose,its adverse effect profile may preclude its use in certain populations.In addition,some patients may require persistent use of IV vasopressors for hypotension refractory to midodrine.The use of additional and alternative oral vasoactive agents bearing different mechanisms of action is emerging.This article provides a comprehensive review of the pharmacology,clinical uses,dosing strategies,and safety considerations of oral vasoactive agents and their application in the inten-sive care setting.

关 键 词：VASOPRESSOR Shock HYPOTENSION Midodrine DROXIDOPA ATOMOXETINE PSEUDOEPHEDRINE 

分 类 号：R96[医药卫生—药理学]